A5067025441- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Protease and Inhibitor Mechanisms
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- MicroRNA in disease regulation
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Inhalation and Respiratory Drug Delivery
- Cancer-related molecular mechanisms research
- Blood Coagulation and Thrombosis Mechanisms
- Pancreatic and Hepatic Oncology Research
- Thyroid Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Occupational and environmental lung diseases
- Pulmonary Hypertension Research and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Myasthenia Gravis and Thymoma
- IL-33, ST2, and ILC Pathways
- RNA Interference and Gene Delivery
- Growth Hormone and Insulin-like Growth Factors
- Molecular Biology Techniques and Applications
- Insect Resistance and Genetics
University Hospital of Zurich
2019
National Institute of Public Health
2019
Instytut Gruźlicy i Chorób Płuc
2008-2017
Weatherford College
2012
Collegium Medicum in Bydgoszcz
2006-2007
Nicolaus Copernicus University
2006-2007
University of Bydgoszcz
2004
The analysis of plasma cell-free DNA (cfDNA) is expected to provide useful biomarkers for early diagnosis non-small-cell lung cancer (NSCLC). However, it remains unclear whether the intense release cfDNA into bloodstream NSCLC patients results from malignancy or chronic inflammatory response. Consequently, current diagnostic utility quantification has not been thoroughly validated in subjects with respiratory inflammation. Here we assess effect inflammation on levels and evaluate potential...
The development of targeted therapies for non-small cell lung cancer (NSCLC), such as the epidermal growth factor receptor ( EGFR), anaplastic lymphoma tyrosine kinase ALK), and ROS proto-oncogene 1 ROS1), has improved patients’ prognosis significantly extended progression-free survival. However, it remains unclear why some patients do not benefit from treatment much or have a rapid disease progression. It is considered that, apart oncogenic driver gene, molecular alterations in number...
Objective: Minute amounts of free-circulating DNA are present in plasma healthy individuals, whereas its increased concentration was observed patients with malignant tumors including non-small cell lung cancer (NSCLC). This study aimed at demonstrating the potential usefulness monitoring NSCLC for therapy effectiveness assessment throughout treatment and follow-up period. Methods: Plasma assessed 50 (stage I – IIIA) prior following radical using real-time quantitative PCR method. 10...
MicroRNAs (miRNAs), key regulators of gene expression at the post-transcriptional level, are grossly misregulated in some human cancers, including non-small-cell lung carcinoma (NSCLC). The aberrant specific miRNAs results abnormal regulation components signalling pathways tumour cells. MiRNA levels and activity targets, oncogenes suppressors, produce feedback that changes miRNA indicates cell's genetic activity. In this study, we measured five circulating (miR-195, miR-504, miR-122, miR-10b...
A better understanding of the molecular pathogenesis thymic epithelial tumours (TETs) could revolutionise their treatment. We evaluated thymomas and carcinomas by next-generation sequencing (NGS) somatic or germline single nucleotide variants (SNVs) in genes commonly mutated solid tumours. In total, 19 34 were analysed for nonsynonymous SNVs 15 targeted NGS (reference genome: hg19/GRCh37). Ten TP53 (G154V, R158P, L194H, R267fs, R273C, R306 *, Q317 *), ERBB2 (V773M), KIT (L576P), KRAS (Q61L)...
Combining neo-adjuvant chemotherapy and surgery is part of multimodality treatment malignant pleural mesothelioma (MPM), but not all patients benefit from this approach. In exploratory analysis, we investigated the prognostic value circulating miR-625-3p lncRNA GAS5 after chemotherapy. 36 MPM SAKK 17/04 trial (NCT00334594), whose blood was available before were investigated. RNA isolated plasma reverse transcribed into cDNA. miR-16-5p β-actin used as a reference gene for GAS5, respectively....
The emergence of targeted therapies in non-small-cell lung cancer (NSCLC), including inhibitors epidermal growth factor receptor (EGFR) tyrosine kinase, has increased the need for robust companion diagnostic tests. Nowadays, detection actionable variants exons 18-21 EGFR gene by qPCR and direct DNA sequencing is often replaced next-generation (NGS). In this study, we evaluated usefulness NGS druggable testing clinical NSCLC material previously analyzed IVD-certified test with respect to...
The exact role of FasL, and particularly its soluble membrane-bound forms, in the development chronic ILDs lung fibrosis has not been extensively explored. We aimed at analyzing FasL expression on alveolar macrophages (AM) lymphocytes (AL) as well (sFasL) levels bronchoalveolar lavage (BAL) from patients, incl. pulmonary sarcoidosis (PS), hypersensitivity pneumonitis (HP), silicosis, asbestosis, idiopathic (IPF), nonspecific interstitial pneumonia (NSIP), healthy subjects (n = 89, 12, 7, 8,...
Previous studies have suggested that hepatocyte growth factor (HGF) inhibits lung fibrosis as an antagonist of transforming β (TGF‑β). We assessed HGF expression levels in the lower airways patients with selected interstitial diseases. were examined by enzyme‑linked immunosorbent assay bronchoalveolar lavage (BAL) fluid supernatants from pulmonary sarcoidosis (PS, n = 52), idiopathic (IPF, 23), nonspecific pneumonia (NSIP, 14), extrinsic allergic alveolitis (EAA, 6), bronchiolitis obliterans...
The detection of epidermal growth factor receptor (EGFR) mutations in plasma cell-free DNA (cfDNA) is an auxiliary tool for the molecular diagnosis non-small cell lung cancer (NSCLC), especially when adequate tumor tissue specimen cannot be obtained. We compared diagnostic accuracy two commonly used vitro diagnostic-certified allele-specific quantitative PCR assays detecting cfDNA EGFR mutations.We analyzed from 90 NSCLC patients (stages I-IV) before treatment (n = 60) and after clinical...